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A hallmark of clear cell renal cell carcinoma (ccRCC) is the presence of intracellular
lipid droplets (LD) and it is assumed that phosphatidic acid (PA) produced by phos-
pholipase D (PLD) plays some role in the LD formation. However, little is known
about the significance of PLD in ccRCC. In this study, we examined the expression
levels of PLD in ccRCC. The classical mammalian isoforms of PLD are PLD1 and
PLD2, and the levels of both mRNA were higher at the primary tumor sites than in
normal kidney tissues. Similarly, both PLD were significantly abundant in tumor cells
as determined by analysis using immunohistochemical staining. Importantly, a higher
level of PLD was significantly associated with a higher tumor stage and grade.
Because PLD2 knockdown effectively suppressed the cell proliferation and invasion
of ccRCC as compared with PLD1 in vitro, we examined the effect of PLD2 in vivo.
Notably, shRNA-mediated knockdown of PLD2 suppressed the growth and invasion
of tumors in nude mouse xenograft models. Moreover, the higher expression of
PLD2 was significantly associated with poorer prognosis in 67 patients. As for genes
relating to the tumor invasion of PLD2, we found that angiogenin (ANG) was posi-
tively regulated by PLD2. In fact, the expression levels of ANG were elevated in
tumor tissues as compared with normal kidney and the inhibition of ANG activity
with a neutralizing antibody significantly suppressed tumor invasion. Overall, we
revealed for the first time that PLD2-produced PA promoted cell invasion through
the expression of ANG in ccRCC cells.
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1 | INTRODUCTION
Renal cell carcinoma (RCC) accounts for approximately 3% of all
adult malignancies and there has been a continuous increase of
new cases during the most recent 10-year period.1,2 Approximately
one-quarter of patients with RCC present with locally advanced or
metastatic disease at diagnosis, and approximately 20%-40% of
those with confined primary tumors will develop metastatic disease.3
Although new target therapies and immunotherapies have emerged,1
their efficacy is not sufficient to overcome advanced RCC.
Phospholipase D (PLD) catalyzes the hydrolysis of phosphatidyl-
choline into phosphatidic acid (PA) and choline. The classical mam-
malian isoforms of PLD are PLD1 and PLD2.4,5 As a lipid second
messenger, PA produced by PLD plays roles in numerous essential
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cellular functions, such as vesicular trafficking, exocytosis, autophagy
and the regulation of cellular metabolism.6 A hallmark of clear cell
RCC (ccRCC), the most common histological type of RCC, is the pres-
ence of intracellular lipid droplets (LD), which consist of a neutral lipid
core containing triglycerides and cholesterol-esters surrounded by a
phospholipid monolayer.7 Although it has been reported that PA pro-
duced by PLD promotes the formation of intracellular LD,8-10 Wetter-
sten et al11 showed that LD was lost in the high grade Fuhrman 4 or
spindle cell type. Interestingly, a previous report showed that the
expression and the activity of PLD2 was elevated in ccRCC;12 how-
ever, little is known about the roles of PLD in the tumor progression
of ccRCC.
We previously reported the significant roles of PLD1 in the
tumor microenvironment of a mouse melanoma lung metastasis
model, showing that the administration of the PLD inhibitor led to a
significant reduction of tumor angiogenesis and metastases.13
Importantly, the elevated expression and the activity of PLD were
associated with cancer proliferation,14 survival,15 invasion and metas-
tasis15-18 in a series of human cancers.19
Based on the above findings, we have examined the roles of
PLD in the tumor progression of ccRCC. In this report, it was
revealed that PLD2 promoted tumor growth and the invasion of
ccRCC cells, and the level of PLD2 in a tumor specimen was signifi-
cantly correlated with the prognoses of patients. Moreover, we clari-
fied a new mechanism of PLD2-mediated cell invasion through the
induction of angiogenin (ANG). Our results suggest that PLD2 might
become a new therapeutic target in the treatment of advanced RCC.
2 | MATERIALS AND METHODS
2.1 | Patients and clear cell renal cell carcinoma
samples
Samples of primary sites from 67 patients who received radical or par-
tial nephrectomy were obtained at Tsukuba University Hospital
between 2006 and 2015 under the protocols approved by the Ethics
Committee of Tsukuba University. These samples were used as forma-
lin-fixed and paraffin-embedded (FFPE) tissue sections of the primary
sites. In 52 of 67 patients, frozen tissue samples of the cancer and
adjacent normal region were available for the primary sites. These
samples were used for extracting RNA. Among 67 patients, 16 under-
went metastasectomy or biopsy of the metastatic site. These samples
were used for FFPE tissue sections of the metastatic sites.
The patient characteristics of tumor stages were assigned
according to the TNM staging of the Union for International Cancer
Control.20 Pathological grades were classified according to the 4-
tiered Fuhrman grading system.21 The characteristics of the patients
are summarized in Table S1.
2.2 | Immunohistochemistry
Formalin-fixed and paraffin-embedded specimens were cut into
4-lm-thick sections. The sections were deparaffinized and
rehydrated. For antigen retrieval, the sections were pretreated by
microwave for 21 minutes in a citric acid buffer. After the antigen
retrieval procedure, endogenous peroxidase activity was blocked
with 3% H2O2 for 25 minutes, and the slides were incubated with
the primary antibody at 4°C overnight. The immunohistochemical
reaction was visualized using the secondary antibody Histofine
Simple Stain MAX PO (Nichirei Bioscience, Tokyo, Japan) with
diaminobenzidine as the chromogen. The primary antibodies were
listed in Table S2. To evaluate the protein expression of PLD1
and PLD2, the staining intensities of tumor cells were stratified
into high and low subgroups. When tumor cells were strongly
stained in not only cell membrane but also cytoplasm, we defined
this as high expression. The other cases were defined as low
expression.
2.3 | Cell culture
293T was purchased from RIKEN BioResource Center (Ibaraki,
Japan). SKRC52 and SKRC59 cells were kindly gifted by Dr JG Old
(Memorial Sloan Kettering Cancer Center, NY, USA). These cell lines
were cultured in RPMI 1640 medium or DMEM supplemented with
10% FBS at 37°C and a 5% humidified CO2 atmosphere.
2.4 | Quantitative RT-PCR
Gene expression levels were quantitatively measured using a 7500
Fast Real-Time PCR machine with Fast SYBR Green Master Mix
(Applied Biosystems). Hypoxanthine phosphoribosyltransferase 1
(HPRT) was used as an internal control. The primer sequences were
listed in Table S3.
2.5 | Western blot analysis
Western blot analysis was carried out as described previously.22
The primary antibody concentrations used for western blot analysis
are listed in Table S4. As a secondary antibody, anti-rabbit or anti-
mouse immunoglobulin G, HRP-linked whole donkey Ab (GE
Healthcare), was used at 1:10 000. Western blots were visualized
with ImmunoStar Zeta (Wako, Tokyo, Japan) using a Fujifilm LAS-
4000 imager (Fujifilm, Tokyo, Japan). b-actin was used as an inter-
nal control.
2.6 | siRNA-mediated expression knockdown
experiments
SKRC52 and SKRC59 cells were transfected with 25 nmol/L of ON-
TARGETplus human PLD1 SMART pool siRNA (L-009413-00-0005,
Dharmacon, Thermo Fisher Scientific, Rockford, IL, USA), 25 nmol/L
of ON-TARGETplus human PLD2 SMART pool siRNA (L-005064-00-
0005) or 25 nmol/L of ON-TARGETplus non-targeting pool siRNA
(D-001810-10-05) using Lipofectamine RNAiMax Reagent (Invitro-
gen). Pooled siRNA containing 4 different target sequences was used
to eliminate the possibility of off-target effects.
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2.7 | Construction of plasmids
The shRNA for PLD2 characterized in previous reports23,24 were
subcloned into the lentiviral vector pLKO.1. The oligonucleotide
sequences used in the construction of the shRNA vector are listed
in Table S5.
2.8 | Lentivirus production and transduction
Lentiviruses were generated in 293T cells by cotransfecting 4
plasmids including the lentiviral vector (pLKO-shControl or pLKO-
shPLD2), pMDLg/pRRE, pRSV-Rev and pMD2.G using Lipofec-
tamine 2000 Reagent (Invitrogen). At 48 hours post-transfection,
virus-containing supernatants were collected for infection. For viral
transductions, the pLKO-shControl or pLKO-shPLD2 lentiviruses
were incubated with SKRC52 and SKRC59 cells overnight at 37°C
in a humidified cell culture incubator. Twenty-four hours post-
infection, cells were selected in the presence of 1.5 lg/mL
puromycin.
2.9 | Cell proliferation and invasion assays
Cell proliferation was assessed by MTT assay using Cell Counting
Kit-8 (Dojindo, Kumamoto, Japan) according to the manufacturer’s
protocol. Briefly, cells were seeded into 96-well plates, and 10 lL of
WST-8 was added after 24, 48, 72 and 120 hours. The OD were
measured after 1-hour incubation. Cell invasion was assayed using a
BioCoat Matrigel invasion chamber (#354480, Corning, Corning, NY,
USA) according to the manufacturer’s protocol. A cell suspension of
5 9 105 in 0.5 mL medium was added into each well of the upper
chamber. As a chemoattractant, 3 nmol/L EGF was used. After
22 hours, the non-invading cells that remained on the upper surface
of the membrane were removed by scraping. The number of invasive
cells was then counted under a microscope. The assays were per-
formed in triplicate in at least 2 independent experiments, and 5
fields were counted per transwell filter.
2.10 | Reagents
Neutralizing antibodies against human ANG were purchased from
R&D Systems (AB-265-NA). The neutralizing antibody or control
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F IGURE 1 The abundance of PLD1 and
PLD2 in corresponding normal and tumor
tissues. A, The level of PLD1 or PLD2
mRNA expression in clinical specimens. P-
value was assessed by the Wilcoxon rank
sum test. B,C, Representative images of
immunohistochemical staining of PLD1 (B)
or PLD2 (C). (1) Normal tissue. (2) Primary
tumor exhibiting low staining intensity. (3)
Primary tumor exhibiting high staining
intensity. (4) Negative control of (3)
stained with a control antibody (rabbit
IgG). Scale bar, 50 lm
TABLE 1 Correlation of PLD1 protein expression and
clinicopathological factors
High PLD1 (n = 18) Low PLD1 (n = 49)
P-valuen (%) n (%)
Age: mean  SD 67.4  12.4 66.0  10.8 .5474
Clinical stage
1-2 4 (22.2) 29 (59.2) .0121*
3-4 14 (77.8) 20 (40.8)
Pathological stage
T1-2 4 (22.2) 32 (65.3) .0023*
T3-4 14 (77.8) 17 (34.7)
Grade
G1-2 3 (16.7) 35 (71.4) .0001*
G3-4 15 (83.3) 14 (28.6)
*Statistically significant difference (P < .05).
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goat IgG was added into each well of the upper chamber for cell
invasion assays. The dose of the neutralizing antibody for use was
determined based on the results of the cell invasion assays at each
dose (Figure S1).
The recombinant human ANG was purchased from R&D Systems
(AB-265-AN-050). The recombinant was diluted at 10 lg/mL in
0.1% BSA. The concentration of use was determined at 0.5 lg/mL
as described previously.26 The recombinant or control (0.1% BSA)
were added into each well of the upper chamber for cell invasion
assays.
2.11 | Lipid preparation
The phospholipid 1,2,-dioleyl phosphatidic acid (DOPA) was pur-
chased from Avanti Polar Lipids (840875P, Alabaster, AL, USA). Lipid
preparation was carried out as described previously.27 Briefly, DOPA
was prepared from powder in PBS with 0.5% BSA for a final concen-
tration of 1 mmol/L. This solution was sonicated and extruded.
Lipids were added to the cells for a final concentration of 300 nmol/
L for 4 hours. Previous reports have shown that this form of PA is
cell soluble.27 Post-treatment cells were harvested and subjected to
quantitative RT-PCR (qRT-PCR).
2.12 | Node mouse xenograft assays
Female 6 to 8-week-old Balb/c nude (nu/nu) mice were purchased
from Charles River Laboratories Japan (Yokohama, Kanagawa, Japan).
For subcutaneous xenograft assays, 5 9 106 cells were injected sub-
cutaneously into the right flanks, and the tumor volumes were mea-
sured once a week. After 10 weeks, the animals were killed and the
xenograft tumors were excised. Orthotopic xenograft was performed
as described previously.28 After the kidney was exposed,
1 9 106 cells were injected into the renal parenchyma. The mice
were killed at 12 weeks after injection. The presence of a tumor
mass was finally confirmed by H&E staining. All animal studies were
approved by the Animal Experiment Committee of the University of
Tsukuba, and all the experiments were performed in accordance with
the guidelines of the University of Tsukuba’s Regulations of Animal
Experiments.
2.13 | Statistical analysis
Data are expressed as means  SD. All statistical analysis was per-
formed using JMP 10 software (SAS Institute, Cary, NC, USA). The
significance of the differences between the 2 groups was assessed
by Student’s t test, Fisher’s exact test and the Wilcoxon rank sum
test. Survival curves were constructed using the Kaplan–Meier
method, and the difference between the curves was evaluated using
the log-rank test. To identify the prognostic factors for overall sur-
vival (OS), PLD2 expression and clinicopathological variables were
evaluated by Cox’s proportional hazard regression model. P-
values < .05 were considered statistically significant.
Additional materials and methods are detailed in Data S1.
3 | RESULTS
3.1 | Expression levels of PLD1 and PLD2 are
associated with tumor progression of clear cell renal
cell carcinoma
To clarify the roles of PLD1 and PLD2 in the tumor progression of
ccRCC, we first examined the abundance of both phospholipases in
corresponding normal and tumor tissues in all 52 cases. It was
revealed that both PLD1 and PLD2 mRNA were significantly more
highly expressed in tumor tissues than normal tissues (Figure 1A). In
tumor specimens, both were positively stained mainly in the cyto-
plasm of ccRCC cells. In normal specimens, heterogeneous staining of
PLD1 and PLD2 were observed in renal tubules (Figure 1B,C). The
staining intensities of tumor cells were subsequently stratified into
high and low subgroups, and the association between the expression
of PLD proteins and clinicopathological factors was examined. It was
revealed that higher PLD1 expression was significantly associated
with worse clinical stage as well as higher tumor stage and Fuhrman
grade (Table 1). Similarly, high PLD2 expression was significantly cor-
related with worse clinical stage and higher tumor grade (Table 2).
Collectively, these results indicated that higher expression of PLD
was related to the disease progression of ccRCC.
3.2 | Inhibition of PLD2 effectively suppressed cell
proliferation and tumor invasion of clear cell renal
cell carcinoma in vitro
To clarify the roles of PLD in the disease progression of ccRCC, we
performed siRNA knockdown of PLD1 or PLD2 in 2 different VHL/
ccRCC cell lines, SKRC52 and SKRC59, respectively. The effects of
each siRNA were evaluated by western blot analysis, and the specific
inhibition was confirmed (Figure 2A). Then, we performed MTT assays
to examine the effect of the siRNA knockdown of each protein on the
cell proliferation. As shown in Figure 2B, the knockdown of PLD2
TABLE 2 Correlation of PLD2 protein expression and
clinicopathological factors
High PLD2 (n = 20) Low PLD2 (n = 47)
P-valuen (%) n (%)
Age: mean  SD 68.7  11.0 65.4  11.2 .3511
Clinical stage
1-2 4 (20.0) 29 (61.7) .0029*
3-4 16 (80.0) 18 (38.3)
Pathological stage
T1-2 6 (30.0) 30 (63.8) .0159*
T3-4 14 (70.0) 17 (36.2)
Grade
G1-2 7 (35.0) 31 (66.0) .0304*
G3-4 13 (65.0) 16 (34.0)
*Statistically significant difference (P < .05).
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significantly inhibited the cell proliferation of both cells compared to
control siRNA. In contrast, no significant effect was observed in the
cell proliferation of cells treated with siRNA against PLD1.
We also evaluated the effect of both proteins on the cell migra-
tion by using a Matrigel invasion assay (Figure 2C). It was revealed
that knockdown of PLD2 significantly suppressed cell invasion in
both cells. Notably, PLD2 knockdown more effectively suppressed
tumor invasion in both cells compared with PLD1 knockdown. Then,
we examined the effect of 2 different PLD inhibitors, FIPI and
NFOT, on the cell proliferation and invasion of ccRCC cells. Both
inhibitors possessed anti-cancer effects for breast cancer cells in
recent studies.14,17 FIPI acted as a dual PLD inhibitor and NFOT
exhibited a specific inhibitory effect only for PLD2. Both inhibitors
significantly suppressed cell proliferation and invasion compared with
the control (Figures S2,S3). NFOT, the PLD2-specific inhibitor, sup-
pressed cell invasion effectively as compared with FIPI. These results
further supported the findings that PLD2 mainly promotes cell prolif-
eration and invasion in renal cancer cells.
3.3 | Knockdown of PLD2 in clear cell renal cell
carcinoma cells suppresses tumor growth and
invasion in vivo
Next, we examined the roles of PLD2 in the tumor progression of
ccRCC in vivo. For this purpose, SKRC52 cells with stably knocked-
down PLD2 were established using 2 different shRNA (#1 and #2)
and both successfully reduced the level of PLD2 without affecting
that of PLD1 (Figure 3A). Importantly, the shRNA-mediated knocking
down of PLD2 suppressed the tumor growth when the cells were
implanted subcutaneously (Figure 3B). We also examined the Ki-67
index in xenograft tumors infected with scramble or PLD2 shRNA,
and it was revealed that SKRC52/PLD2 shRNA cells exhibited a sig-
nificantly lower Ki-67 index than did SKRC52/scramble cells (Fig-
ure 3C). These results further supported the possibility that PLD2
augmented the tumor growth in vivo. Then, we performed ortho-
topic xenograft assays to examine whether PLD2 also regulates the
invasive ability of SKRC52 cells in vivo. Pathological examination of
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F IGURE 2 The effects of the siRNA
knockdown of phospholipase D (PLD) on
cell growth and invasion in clear cell renal
cell carcinoma (ccRCC) cell lines. A,
Western blot analysis of SKRC52 and
SKRC59 transfected with control, PLD1 or
PLD2 small interfering RNA. Whole-cell
extracts were analyzed by immunoblotting
using the indicated antibodies. B, Analysis
of cell proliferation by MTT assay after
transfection with siRNA. C, Analysis of cell
invasion ability using a Matrigel invasion
assay after transfection with siRNA. P-
value was assessed by Student’s t test
(*P < .05, **P < .01, ***P < .001)
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tumors implanted in an orthotopic site revealed that SKRC52/PLD2
shRNA cells hardly invaded into normal tissue, although SKRC52/
scramble cells extensively infiltrated into the parenchyma of the nor-
mal kidney (Figure 3D). These results indicate that PLD2 augmented
the cell invasion ability in those cells in vivo.
3.4 | Elevated expression of PLD2 is associated
with poor prognosis in clear cell renal cell carcinoma
Based on the above results, we examined the association between
the expression of PLD2 and the prognosis of patients to elucidate
the clinical impact of this protein in ccRCC. A Kaplan-Meier analy-
sis revealed that the high expression of PLD2 was significantly
associated with a poor patient prognosis (P = .002, Figure 4A). We
also examined whether PLD2 expression would be an independent
RCC prognostic factor. We employed univariate and multivariate
Cox regression analyses with clinical stage, grade, microvascular
invasion and PLD2 expression. Both univariate and multivariate
analyses revealed that PLD2 expression was an independent prog-
nostic marker for RCC patient OS (Table 3). Because PLD2 pro-
moted the tumor invasion of ccRCC in mice xenograft models, we
also examined the abundance of this protein in tumor cells invading
microvessels. Intriguingly, abundant expression of PLD2 was
observed in the site of microvascular invasion in 8 out of 10 cases
(Figure 4B). Moreover, the protein expression levels of PLD2 in the
metastatic sites were significantly elevated compared with the pri-
mary sites (P < .01, Figure 4C,D). Collectively, these results strongly
suggested that PLD2 significantly affected the prognosis of patients
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staining of SKRC52 xenograft tumors
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scramble or PLD2 shRNA. The labeling
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shown. P-value was assessed by the
Wilcoxon rank sum test (*P < .05). Scale
bar 50 lm. D, Orthotopic implantation of
SKRC52 cells infected with scramble or
PLD2 shRNA for the evaluation of invasive
ability in vivo. Margins of tumors are
indicated by a dotted line. N, normal
kidney tissue; T, tumor. Scale bar, 50 lm
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through the regulation of the invasion ability and tumor metastasis
of ccRCC.
3.5 | Angiogenin regulated by lipase activity of
PLD2 promotes cell invasion in renal cancer cells
Finally, we examined the mechanisms of PLD2 in promoting the
tumor invasion and metastasis of ccRCC. Toward this end, we com-
pared the expression profile of SKRC52/scramble and SKRC52/
PLD2 shRNA cells (#1 and #2) using a qRT-PCR array. Among 168
genes involved in angiogenesis and tumor invasion, we identified 12
genes whose expression was altered at least 1.5-fold by both shRNA
(Table S6). Among them, ANG was identified as a gene downregu-
lated by 2 different PLD2 shRNA. This result was confirmed by qRT-
PCR analysis using another set of primers and the cell line in
SKRC59 (Figure 5A). Importantly, the mRNA levels of ANG were ele-
vated in ccRCC as compared with normal kidney (Figure 5B).
To clarify the significance of ANG in the invasion ability and tumor
metastasis of ccRCC, we examined the effects of this protein in cell
invasion by using a Matrigel invasion assay. Inhibiting ANG activity
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F IGURE 4 PLD2 protein levels are correlated with poor prognosis and are elevated in the sites of metastasis in patients with clear cell renal
cell carcinoma (ccRCC). A, Kaplan-Meier curves of the overall survival of 67 ccRCC patients, with regard to the PLD2 protein level of primary
tumors. P-value was assessed by the log-rank test. B, PLD2 staining of primary tumor and microvascular invasion site in a representative patient
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TABLE 3 The univariate and multivariate analysis of prognostic factors on overall survival
Cox proportional hazard model
(univariate)
Cox proportional hazard model
(multivariate)
HR 95% CI of HR P HR 95% CI of HR P
Clinical stage (1-2 vs 3-4) 17.6 3.38-323 .0001* 2.97 0.10-91.1 .4889
Grade (1-2 vs 3-4) 17.8 3.45-326 <.0001* 8.99 1.18-202 .0318*
Microvascular invasion 9.38 2.46-61.2 .0006* 1.37 0.07-8.52 .7840
PLD2 (low vs high) 11.4 2.39-30.7 .0007* 4.33 1.25-18.5 .0204*
*Statistically significant difference (P < .05).
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with a neutralizing antibody significantly suppressed cell invasion in
SKRC52 and SKRC59 cells transfected with scramble shRNA (Fig-
ure 5C). Conversely, treatment with recombinant human ANG signifi-
cantly promoted the cell invasion ability of both cells with shRNA
mediated knockdown of PLD2 (Figure 5D). We further examined if
the expression of ANG was promoted by PLD2 through the produc-
tion of PA in renal cancer cells. Although ANG mRNA was downregu-
lated by the knockdown of PLD2, the reduced expression was
augmented by the treatment with PA in the same cells (Figure 5E).
Collectively, these results demonstrated that PLD2-produced PA
promotes cell invasion in ccRCC cells, at least in part through regu-
lating ANG.
4 | DISCUSSION
Phospholipase D expression and activity have been previously
reported to be elevated in various human cancers such as colorectal,
gastric, breast and kidney cancers when compared with adjacent
non-cancer tissues.12,19,29 The elevated expression of PLD2 was cor-
related with poor prognosis in colorectal cancer.29 Moreover, previ-
ous studies demonstrated that PA produced by PLD promoted
cancer proliferation, invasion and metastasis by various activated cell
signaling pathways such as AKT and ERK signaling.6,14-18
In the present study, we showed that the elevated expression of
PLD2 was associated with poor prognosis, and that PLD2 ablation
and PLD2 small-molecule inhibitors suppressed the cell proliferation
and invasion of renal cancer cells in vitro. We also revealed that
PLD2 knockdown inhibited tumor growth and invasion using human
renal cancer subcutaneous and orthotopic xenograft models. In
keeping with previous reports, we confirmed that PLD2 regulated
the phosphorylation of AKT and ERK in human renal cancer cells
(Figure S4). These findings suggest that AKT and ERK signaling acti-
vated by PLD2-produced PA might contribute to promoting tumor
progression in ccRCC.
In the present study, we focused on ANG as the downstream tar-
get of PLD2 in genes related to angiogenesis and tumor invasion
based on the results of PCR-array analysis. ANG, a 14-kDa member
of the pancreatic ribonuclease superfamily, was originally isolated
from the conditioned medium of HT-29 human colon adenocarci-
noma cells.30 ANG is a multifunctional secreted protein, which has
been previously reported to play important roles in proliferation,
invasion and metastasis coupled with the mediation of angiogenesis
in several types of human cancer.31-34 Yoshioka et al35 showed that
the protein levels of ANG were elevated in human cancers including
ccRCC by immunohistochemical analysis. Previous studies further
showed that the levels of serum ANG in patients with ccRCC were
elevated in comparison with healthy controls.36,37 However, the reg-
ulation and potential roles of ANG remain to be elucidated in ccRCC.
In the present study, we revealed for the first time that the produc-
tion of PA by PLD2 regulated the expression of ANG, and that ANG
promoted cell invasion in renal cancer cells.
As shown in Table S6, we also identified collagen type VIII
alpha-1 chain (COL8A1) as a gene downregulated by 2 different
PLD2 shRNA. This result was confirmed by qRT-PCR analysis using
another set of primers in 2 different ccRCC cell lines (Figure S5).
COL8A1 is one of the 2 alpha chains of collagen type VIII, classified
as a non-fibrillar short-chain collagen. Zhao et al38 demonstrated
that siRNA-targeted COL8A1 inhibits proliferation and invasion in
hepatocarcinoma cells. Because mRNA of COL8A1 were elevated in
ccRCC specimens as compared with normal kidney (Figure S6), we
speculate that COL8A1 is also related with ccRCC progression
through promoting cell proliferation and invasion.
Previous reports demonstrated that not only PLD2 but also
PLD1 promoted tumor invasion in several cancers.6,18,39 Because
high PLD1 expression was associated with higher tumor stage and
worse clinical stage in patients with ccRCC (Table 1), we examined
the roles of PLD1 in the regulation of ANG. In fact, it was revealed
that the expression of ANG was suppressed by the knockdown of
PLD1 (Figure S7). We also examined the abundance of this protein
in the metastatic sites and compared it with that in the primary sites.
However, the protein expression levels of PLD1 in the metastatic
sites were not significantly elevated compared with the primary sites
in our series of RCC samples (Figure S8). Collectively, PLD2 might
play main roles in the tumor metastasis of ccRCC among 2 different
PLD.
In the present targeted therapies for metastatic RCC, tyrosine
kinase inhibitors (TKI) suppress the downstream targets of hypoxia-
inducible factor (HIF) pathways such as VEGF and PDGF receptors.
Although the tumor volume is decreased by TKI, there are few cur-
able patients. As shown in the present study, PLD2 promoted a vari-
ety of cancer progression-related signaling in renal cancer cells. In
addition, the expression of PLD2 was higher in microvascular inva-
sion and in the metastatic sites of patients with ccRCC. Therefore,
PLD2 is a new potential target of treatment for metastatic RCC. The
development of targeting PLD isoenzymes with small molecule inhi-
bitors has steadily proceeded from 2000s since PLD family members
were implicated in a variety of human diseases such as viral infec-
tions, neurodegeneration and cancer.40 Although there remain some
problems such as off-target activity and PLD isoform selectivity in
F IGURE 5 PLD2 promotes cell invasion through the regulation of ANG in SKRC52 and SKRC59 cells. A, Evaluation of the mRNA
expression of ANG of SKRC52 and SKRC59 cells infected with scramble or PLD2 shRNA. P-value was assessed by Student’s t test (*P < .05,
**P < .01, ***P < .001). B, The mRNA expression of ANG in 52 clear cell renal cell carcinoma (ccRCC) patients. P-value was assessed by
Wilcoxon rank sum test. C, Analysis of cell invasion ability after treatment with ANG-neutralized antibody to control IgG. P-value was assessed
by Student’s t test (*P < .05, **P < .01, ***P < .001). D, Analysis of cell invasion ability after treatment with recombinant human ANG protein
to control (0.1%BSA). P-value was assessed by Student’s t test (*P < .05, **P < .01, ***P < .001). E, The effect of PA on the mRNA expression
of ANG in SKRC52 and SKRC59 infected with PLD2 shRNA. P-value was assessed by Student’s t test (*P < .05, **P < .01, ***P < .001)
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PLD inhibitors, new efficacious PLD2 inhibitors for metastatic RCC
might emerge in future.
In conclusion, we revealed that the elevated expression of PLD2
was associated with a poor prognosis and promoted tumor growth
and invasion in ccRCC. We also demonstrated the new finding that
PLD2-PA-ANG signaling promotes cell invasion in renal cancer cells.
Our results provide the first evidence that targeting PLD2 is a good
candidate for future therapeutic and clinical applications against
metastatic RCC.
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